11:08 AM
Jan 19, 2018
 |  BioCentury  |  Finance

Incubating in China

Why C-Bridge is writing big checks to bring Western platforms into China

C-Bridge Capital is one of the newer venture funds in Chinese healthcare seeking to bring mature platforms or programs from the Western market into China. Compared with most other Chinese VCs, however, C-Bridge is investing larger sums of capital into a relatively small portfolio.

And while C-Bridge cut its teeth on more established companies, the firm is now setting its sights on building more companies from the ground up. Its two most recent investments -- Everest Medicines Ltd. and CMAB Biopharma Inc. -- are examples.

CEO and Managing Director Fu Wei founded C-Bridge in 2014. Fu was previously head of principal investment at Far East Horizon.

C-Bridge’s first fund raised $185 million, and last May the firm closed its second fund at $400 million, well above the $300 million target.

Since 2014, C-Bridge has participated in at least six disclosed biopharma financings with an average of $80.5 million raised.

“It is our way to build a global company in China.”

Sean Cao, Everest

The average is two times higher or more than the most active Chinese healthcare VCs tracked in BioCentury’s BCIQ database during the same period. Qiming Venture Partners has disclosed at least 14 financings with an average raise of $26.4 million, while Lilly Asia Ventures disclosed at least 10 financings with a $40.7 million average.

Three of the seven C-Bridge rounds were $100 million or more, while Qiming and Lilly Asia each had only one financing of that size.

Hillhouse Capital, Temasek, Legend Holdings and State Development &...

Read the full 1254 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >